{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16(5)"],"submitter":["Larenas-Linnemann D"],"pubmed_abstract":["<h4>Introduction</h4>Allergen immunotherapy (AIT) brings along changes in the immune system, restoring dendritic cell function, reducing T2 inflammation and augmenting the regulatory cell activation. Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, interferes with the immune system causing immune suppression during the first phase and over-activation in more advanced disease. We decided to explore the interaction of both in a real-world observational trial.<h4>Methods</h4>We registered COVID-19 outcomes in patients with allergic disorders in Latin America, treated with and without AIT. The registry was conducted during the first 1.3 years of the pandemic, with most of the data collected before COVID-19 vaccination was conclu"],"journal":["The World Allergy Organization journal"],"pagination":["100779"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10154540"],"repository":["biostudies-literature"],"pubmed_title":["Aeroallergen immunotherapy associated with reduced risk of severe COVID-19 in 1095 allergic patients."],"pmcid":["PMC10154540"],"pubmed_authors":["Villa Medica L","Lopez-Bago A","Valle Rodriguez F","Zuniga Reyes CO","Cavallo MC","Repka-Ramirez MS","Chavez-Vereau P","Flores Morales ME","Martinez Guzman E","Ivancevich JC","Sarrazola Sanjuan M","Navarrete Rodriguez EM","Olivares Gomez M","Rodriguez Zagal E","Garcia Cruz MLH","Fernandez De Cordova Aguirre JC","Gallego Corella CI","Huerta Villalobos YR","Bedolla-Barajas M","Piraino Sosa PA","Rodriguez-Gonzalez M","Romero Tapia SJ","Cano Pedroza RY","Larenas-Linnemann D","Luna-Pech JA","Gereda JE","Rivero Yeverino D","Jossen RA","Del Rio Navarro BE","Garcia Imperial DA","Perez Ortiz CE","Fuentes Perez JM","Mogica-Martinez MD","Morfin-Maciel BM"],"additional_accession":[]},"is_claimable":false,"name":"Aeroallergen immunotherapy associated with reduced risk of severe COVID-19 in 1095 allergic patients.","description":"<h4>Introduction</h4>Allergen immunotherapy (AIT) brings along changes in the immune system, restoring dendritic cell function, reducing T2 inflammation and augmenting the regulatory cell activation. Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, interferes with the immune system causing immune suppression during the first phase and over-activation in more advanced disease. We decided to explore the interaction of both in a real-world observational trial.<h4>Methods</h4>We registered COVID-19 outcomes in patients with allergic disorders in Latin America, treated with and without AIT. The registry was conducted during the first 1.3 years of the pandemic, with most of the data collected before COVID-19 vaccination was conclu","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 May","modification":"2026-05-29T13:59:01.391Z","creation":"2025-02-19T03:26:10.025Z"},"accession":"S-EPMC10154540","cross_references":{"pubmed":["37251811"],"doi":["10.1016/j.waojou.2023.100779"]}}